Johann S. de Bono

Johann de Bono is a world-leading authority on advanced prostate cancer drug development, holding the Regius Professorship of Cancer Research at The Institute of Cancer Research (ICR) in London. He leads one of the most productive academic oncology programs in the world, having been the principal investigator or lead investigator on the trials that resulted in FDA approvals of abiraterone acetate (Zytiga), olaparib for prostate cancer (Lynparza), cabazitaxel (Jevtana), and multiple other agents. His work at The Royal Marsden has defined the modern treatment paradigm for castration-resistant prostate cancer. De Bono's early phase clinical trial leadership produced the landmark COU-AA-301 trial of abiraterone in post-docetaxel CRPC, demonstrating a 3.9-month improvement in overall survival and earning FDA approval in 2011. He subsequently led COU-AA-302, which showed abiraterone's activity in chemotherapy-naive CRPC, substantially expanding the eligible population. Mechanistically, his group contributed to understanding the mechanisms of adrenal and intratumoral androgen synthesis that abiraterone targets, as well as the resistance mechanisms that emerge after its use. A leader in precision oncology for prostate cancer, de Bono's group produced the landmark PROfound trial, which demonstrated that olaparib significantly improved radiographic progression-free survival in CRPC patients with homologous recombination repair (HRR) gene alterations — particularly BRCA1/2 mutations — who had progressed on novel hormonal agents. This led to FDA approval of olaparib for CRPC in 2020 and established the importance of germline and somatic HRR testing as a standard of care in advanced prostate cancer.

Johann de Bono 是晚期前列腺癌药物开发领域的世界权威，担任伦敦癌症研究所皇家癌症研究教授。他主导了导致阿比特龙（Zytiga）、奥拉帕尼用于前列腺癌（Lynparza）、卡巴他赛（Jevtana）等多种药物获得 FDA 批准的临床试验，定义了去势抵抗性前列腺癌的现代治疗范式。 在精准肿瘤学领域，de Bono 团队的 PROfound 试验证明奥拉帕尼在具有同源重组修复（HRR）基因改变的 CRPC 患者中显著改善了影像学无进展生存期，特别是 BRCA1/2 突变患者，这直接导致了2020年奥拉帕尼在 CRPC 中的 FDA 批准，并确立了晚期前列腺癌的 HRR 检测标准。